D

Dermatologikum Hamburg | Hamburg, Germany

Research site

(Unclaimed)

Location

5 Stephansplatz, Hamburg, Hamburg, Germany

Site insights

Top conditions

Top treatments

Rocatinlimab

AMG 451

TAK-279

Enbrel

LY3375880

Upadacitinib

Dupilumab

5-FU

CHS-0214

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

Locations recently updated

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling

Plaque Psoriasis

Drug: TAK-279

Drug: Placebo

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

The co-primary objectives of the study are to:* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Inve...

Active, not recruiting

Atopic Dermatitis

Other: Placebo

Drug: Rocatinlimab

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab